CurrentUnitedHealthcarePolicy CS198NM.B

Chemo Observation Inpatient Hospitalization Nm Cs

Defines medical necessity criteria for when chemotherapy administration requires an inpatient hospital stay versus facility observation for UnitedHealthcare members in New Mexico (adults ≥18). Lists specific drug regimens and clinical conditions that require inpatient care and those that may require observation or inpatient care.

Policy Summary

PayerUnitedHealthcare

PolicyChemo Observation Inpatient Hospitalization Nm Cs

Policy CodePolicy CS198NM.B

Change TypeSupporting information updates (clinical evidence/references)

Effective DateApr 1, 2025

Next Review Date

Key ActionA written protocol must be followed by the provider administering the chemotherapy drug.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information; archived previous policy version CS198NM.A

7Example regimens listed requiring inpatient stay or monitoring

3Conditions that require inpatient stay

3Conditions that may require observation stay

1State-specific policy (New Mexico)

This policy defines medical necessity criteria for when chemotherapy administration requires an inpatient hospital stay versus a facility observation visit for UnitedHealthcare members in New Mexico who are 18 years of age or older. It lists specific multi-day or complex drug regimens (for example, EPOCH/DA-EPOCH/R-EPOCH; ESHAP/R-ESHAP; interleukin-2 infusion; high-dose ifosfamide; high-dose methotrexate with leucovorin rescue; Hyper-CVAD) and clinical conditions that either require inpatient care or may require observation, and identifies monitoring, coordination, and risk-mitigation reasons that make inpatient hospitalization medically necessary.

Key thresholds and state-specific note

Methotrexate dose requiring inpatient monitoring> 500 mg/m2

Methotrexate serum level thresholds for leucovorin escalation> 20 µmol/L at 0 hour; > 1.0 µmol/L at 24 hours; > 0.1 µmol/L at 48 hours; continue until levels < 0.1

High-dose ifosfamide threshold> 1 g/m2/day

Coordination window for multi-infusion regimensmultiple infusions or multiple drugs over 96 hours

State-specific noteState-specific: New Mexico only

Medical-Necessity Criteria — General Application

General Application

Applies only to New Mexico and does not apply to individuals under 18 years of age.

ALL of the following

Patient is age 18 years or older
Policy applies to services provided in the state of New Mexico

Medical-Necessity Criteria — Observation Stay

Conditions that may require observation stay

The following clinical conditions or complications of chemotherapy may require an observation stay:

ANY of the following

Known hypersensitivity reactions from previous infusion
High-volume fluid needs: Congestive heart failure or chronic renal failure requiring high volume fluid infusions
TACE or intra-arterial chemo: Transcatheter Arterial Chemoembolization (TACE) or intra-arterial chemotherapy infusion

Medical-Necessity Criteria — Conditions Requiring Inpatient Stay

Conditions that require inpatient hospital stay

The following clinical conditions require an inpatient hospital stay:

ANY of the following

Acute leukemia
Intra-arterial infusion of chemotherapy
TLS prophylaxis: Prophylaxis of tumor lysis syndrome in cases of high-grade lymphoma with large masses

Medical-Necessity Criteria — Other / Case-by-Case Review

Other cases

Cases not specified will be reviewed case-by-case using InterQual criteria

ALL of the following

Case-by-case review: Conditions requiring observation or inpatient hospital treatment other than those noted will be reviewed on a case-by-case basis
InterQual reference: Reference: InterQual LOC: Acute Adult, Hematology/Oncology: Complications or Disease Progression and/or InterQual LOC: Acute Adult Hematology/Oncology: Treatments for medical necessity clinical coverage criteria

Provider Actions

Documentation Required

Written protocol required

A written protocol is required and must be followed by the provider administering the chemotherapy drug.

Documentation Required

Clinical review for inpatient extension

Any requests to extend an inpatient stay beyond the recommended day(s) must undergo clinical review.

Documentation Required

Use InterQual for non-specified cases

Cases not specified in this policy will be reviewed case-by-case using InterQual level-of-care (LOC) criteria: Acute Adult, Hematology/Oncology modules for Complications or Disease Progression and/or Treatments.

Background & Evidence

Most chemotherapy can be given safely in outpatient settings or at home, but certain regimens, high-dose agents, continuous multi-day infusions, intra-arterial procedures, or patient comorbidities create risks that necessitate closer monitoring, complex administration, or supportive measures only available during an observation or inpatient stay. Examples include continuous 96-hour infusion protocols that require coordination of multiple drugs and pumps, therapies requiring continuous cardiac and intensive physiologic monitoring (e.g., interleukin-2), high-risk agents needing electrolyte, urine pH, or methotrexate serum-level monitoring and leucovorin escalation, and procedures such as TACE or intra-arterial chemotherapy. UnitedHealthcare requires a written protocol for administering chemotherapy and clinical review for extensions of inpatient stays; cases not specified are reviewed case-by-case using InterQual criteria.

Citation	Summary
Tirtei et al. 2024	Retrospective multicenter cohort of high-dose ifosfamide showing feasible outpatient administration with manageable toxicity in selected patients
Nelles et al. 2023	Retrospective cohort of DA-EPOCH-R suggesting outpatient delivery feasible with inpatient admission for complications
Multiple observational studies 2019-2022	Support outpatient administration for selected regimens with appropriate monitoring and selection

TACE: Transcatheter Arterial Chemoembolization — a procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor (NCI, 2022).

High-dose methotrexate: methotrexate dose of > 500 mg/m2 with required serum methotrexate monitoring and leucovorin rescue per specified level thresholds.

High-dose ifosfamide: ifosfamide infusion of > 1 g/m2/day requiring close monitoring of serum electrolytes and urine pH with alkalinization and electrolyte replacement.

Revision History

2025-04-01clarifiedLatest

Summary of Changes noted 04/01/2025 indicates supporting information updates only; updated Clinical Evidence and References sections; archived previous policy version CS198NM.A; change not material

2025-04-01effective

Policy effective date: April 1, 2025 (Policy Number CS198NM.B)

2025-04-01last_review

Last review date: April 1, 2025

Policy Summary

PayerUnitedHealthcare

PolicyChemo Observation Inpatient Hospitalization Nm Cs

Policy CodePolicy CS198NM.B

Change TypeSupporting information updates (clinical evidence/references)

Effective DateApr 1, 2025

Next Review Date

Key ActionA written protocol must be followed by the provider administering the chemotherapy drug.

SourceLink

On This Page

OpenPayer

Chemo Observation Inpatient Hospitalization Nm Cs

Coverage Summary

Medical-Necessity Criteria — General Application

Medical-Necessity Criteria — Multi-day / Complex Regimens

Medical-Necessity Criteria — Observation Stay

Medical-Necessity Criteria — Conditions Requiring Inpatient Stay

Medical-Necessity Criteria — Other / Case-by-Case Review

Coding

Provider Actions

Background & Evidence

Revision History